BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32609836)

  • 1. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
    Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
    Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
    Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
    Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
    Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting.
    Fusco R; Galgani M; Procaccini C; Franco R; Pirozzi G; Fucci L; Laccetti P; Matarese G
    Endocr Relat Cancer; 2010 Jun; 17(2):373-82. PubMed ID: 20410173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer.
    Huang B; Omoto Y; Iwase H; Yamashita H; Toyama T; Coombes RC; Filipovic A; Warner M; Gustafsson JÅ
    Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1933-8. PubMed ID: 24449868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.
    Bossart EA; Tasdemir N; Sikora MJ; Bahreini A; Levine KM; Chen J; Basudan A; Jacobsen BM; Burns TF; Oesterreich S
    Breast Cancer Res Treat; 2019 Jun; 175(2):327-337. PubMed ID: 30798422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
    PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
    Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
    Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
    Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
    Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas.
    Takagi M; Miki Y; Miyashita M; Hata S; Yoda T; Hirakawa H; Sagara Y; Rai Y; Ohi Y; Tamaki K; Ishida T; Suzuki T; Ouchi N; Sasano H
    Breast Cancer Res Treat; 2016 Feb; 156(1):45-55. PubMed ID: 26943913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism.
    Du T; Zhu L; Levine KM; Tasdemir N; Lee AV; Vignali DAA; Houten BV; Tseng GC; Oesterreich S
    Sci Rep; 2018 May; 8(1):7205. PubMed ID: 29739984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status.
    Xiao Y; Ma D; Ruan M; Zhao S; Liu XY; Jiang YZ; Shao ZM
    Sci Rep; 2017 Sep; 7(1):10380. PubMed ID: 28871133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.